Phase-3 study targeting amyloid-beta in participants with mild cognitive impairment due to Alzheimer's disease or mild Alzheimer's disease. Please note that this is a re-dosing study that is only open to participants who were previously enrolled in the Aducanumab studies (221AD103, 221AD301, 221AD302, 221AD205).
|Studies ||Biogen 221AD304|
|Required Diagnosis||Alzheimer's disease|
|Length||126 wks (8 wks screening, 100 wks treatment period, 18 wks safety followup after the last dose)|
|Lumbar Puncture||Optional - 3 LPs (1 at screening, 2 during the treatment period)|
|For more information|
NIH Clinical Trials Website: